PROTAC
PROTACs (Proteolysis Targeting Chimeras) are bifunctional small molecules designed to induce selective degradation of target proteins through the ubiquitin–proteasome system. A typical PROTAC molecule consists of a target protein ligand, an E3 ligase ligand, and a linker connecting the two components. Unlike conventional inhibitors, PROTAC technology promotes ubiquitination and degradation of disease-related proteins rather than simply blocking their activity. Widely used in targeted protein degradation research, PROTACs offer a powerful strategy for addressing drug-resistant and traditionally undruggable targets in cancer, neurodegenerative diseases, and other therapeutic areas.
Explore By Category
Targeted Protein Degradation
Targeted protein degradation is an emerging therapeutic strategy that selectively eliminates disease-associated proteins through the cellular ubiquitin–proteasome pathway. PROTAC technology is one of the most advanced targeted protein degradation platforms, enabling catalytic and sustained removal of pathogenic proteins for cancer therapy, neurodegenerative disease research, and drug discovery applications.
E3 Ligase Recruitment
E3 ligase recruitment is a key mechanism in PROTAC design that enables ubiquitination and proteasomal degradation of target proteins. By recruiting E3 ubiquitin ligases such as CRBN or VHL, PROTAC molecules facilitate selective protein degradation with high specificity and therapeutic potential in targeted drug development and chemical biology research.
Featured Sub Categories
